Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Niehaus JZ, Good M, Jackson LE, Ozolek JA, Silverman GA, Luke CJ. Human SERPINB12 Is an Abundant Intracellular Serpin Expressed in Most Surface and Glandular Epithelia. J Histochem Cytochem 2015. [PMID: 26220980 DOI: 10.1369/0022155415600498] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open

For:	Niehaus JZ, Good M, Jackson LE, Ozolek JA, Silverman GA, Luke CJ. Human SERPINB12 Is an Abundant Intracellular Serpin Expressed in Most Surface and Glandular Epithelia. J Histochem Cytochem 2015. [PMID: 26220980 DOI: 10.1369/0022155415600498] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open

Number

Cited by Other Article(s)

Serrath SN, Pontes AS, Paloschi MV, Silva MDS, Lopes JA, Boeno CN, Silva CP, Santana HM, Cardozo DG, Ugarte AVE, Magalhães JGS, Cruz LF, Setubal SS, Soares AM, Cavecci-Mendonça B, Santos LD, Zuliani JP. Exosome Liberation by Human Neutrophils under L-Amino Acid Oxidase of Calloselasma rhodostoma Venom Action. Toxins (Basel) 2023;15:625. [PMID: 37999488 PMCID: PMC10674320 DOI: 10.3390/toxins15110625] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2023] [Revised: 09/20/2023] [Accepted: 10/17/2023] [Indexed: 11/25/2023] Open

Affiliation(s)

Suzanne N. Serrath Laboratório de Imunologia Celular Aplicada à Saúde, Fundação Oswaldo Cruz, FIOCRUZ-Rondônia, Porto Velho 76812-245, RO, Brazil; (S.N.S.); (A.S.P.); (M.V.P.); (M.D.S.S.); (J.A.L.); (C.N.B.); (C.P.S.); (H.M.S.); (D.G.C.); (A.V.E.U.); (J.G.S.M.); (L.F.C.); (S.S.S.)
Adriana S. Pontes Laboratório de Imunologia Celular Aplicada à Saúde, Fundação Oswaldo Cruz, FIOCRUZ-Rondônia, Porto Velho 76812-245, RO, Brazil; (S.N.S.); (A.S.P.); (M.V.P.); (M.D.S.S.); (J.A.L.); (C.N.B.); (C.P.S.); (H.M.S.); (D.G.C.); (A.V.E.U.); (J.G.S.M.); (L.F.C.); (S.S.S.)
Mauro V. Paloschi Laboratório de Imunologia Celular Aplicada à Saúde, Fundação Oswaldo Cruz, FIOCRUZ-Rondônia, Porto Velho 76812-245, RO, Brazil; (S.N.S.); (A.S.P.); (M.V.P.); (M.D.S.S.); (J.A.L.); (C.N.B.); (C.P.S.); (H.M.S.); (D.G.C.); (A.V.E.U.); (J.G.S.M.); (L.F.C.); (S.S.S.)
Milena D. S. Silva Laboratório de Imunologia Celular Aplicada à Saúde, Fundação Oswaldo Cruz, FIOCRUZ-Rondônia, Porto Velho 76812-245, RO, Brazil; (S.N.S.); (A.S.P.); (M.V.P.); (M.D.S.S.); (J.A.L.); (C.N.B.); (C.P.S.); (H.M.S.); (D.G.C.); (A.V.E.U.); (J.G.S.M.); (L.F.C.); (S.S.S.)
Jéssica A. Lopes Laboratório de Imunologia Celular Aplicada à Saúde, Fundação Oswaldo Cruz, FIOCRUZ-Rondônia, Porto Velho 76812-245, RO, Brazil; (S.N.S.); (A.S.P.); (M.V.P.); (M.D.S.S.); (J.A.L.); (C.N.B.); (C.P.S.); (H.M.S.); (D.G.C.); (A.V.E.U.); (J.G.S.M.); (L.F.C.); (S.S.S.)
Charles N. Boeno Laboratório de Imunologia Celular Aplicada à Saúde, Fundação Oswaldo Cruz, FIOCRUZ-Rondônia, Porto Velho 76812-245, RO, Brazil; (S.N.S.); (A.S.P.); (M.V.P.); (M.D.S.S.); (J.A.L.); (C.N.B.); (C.P.S.); (H.M.S.); (D.G.C.); (A.V.E.U.); (J.G.S.M.); (L.F.C.); (S.S.S.)
Carolina P. Silva Laboratório de Imunologia Celular Aplicada à Saúde, Fundação Oswaldo Cruz, FIOCRUZ-Rondônia, Porto Velho 76812-245, RO, Brazil; (S.N.S.); (A.S.P.); (M.V.P.); (M.D.S.S.); (J.A.L.); (C.N.B.); (C.P.S.); (H.M.S.); (D.G.C.); (A.V.E.U.); (J.G.S.M.); (L.F.C.); (S.S.S.)
Hallison M. Santana Laboratório de Imunologia Celular Aplicada à Saúde, Fundação Oswaldo Cruz, FIOCRUZ-Rondônia, Porto Velho 76812-245, RO, Brazil; (S.N.S.); (A.S.P.); (M.V.P.); (M.D.S.S.); (J.A.L.); (C.N.B.); (C.P.S.); (H.M.S.); (D.G.C.); (A.V.E.U.); (J.G.S.M.); (L.F.C.); (S.S.S.)
Daniel G. Cardozo Laboratório de Imunologia Celular Aplicada à Saúde, Fundação Oswaldo Cruz, FIOCRUZ-Rondônia, Porto Velho 76812-245, RO, Brazil; (S.N.S.); (A.S.P.); (M.V.P.); (M.D.S.S.); (J.A.L.); (C.N.B.); (C.P.S.); (H.M.S.); (D.G.C.); (A.V.E.U.); (J.G.S.M.); (L.F.C.); (S.S.S.)
Andrey V. E. Ugarte Laboratório de Imunologia Celular Aplicada à Saúde, Fundação Oswaldo Cruz, FIOCRUZ-Rondônia, Porto Velho 76812-245, RO, Brazil; (S.N.S.); (A.S.P.); (M.V.P.); (M.D.S.S.); (J.A.L.); (C.N.B.); (C.P.S.); (H.M.S.); (D.G.C.); (A.V.E.U.); (J.G.S.M.); (L.F.C.); (S.S.S.)
João G. S. Magalhães Laboratório de Imunologia Celular Aplicada à Saúde, Fundação Oswaldo Cruz, FIOCRUZ-Rondônia, Porto Velho 76812-245, RO, Brazil; (S.N.S.); (A.S.P.); (M.V.P.); (M.D.S.S.); (J.A.L.); (C.N.B.); (C.P.S.); (H.M.S.); (D.G.C.); (A.V.E.U.); (J.G.S.M.); (L.F.C.); (S.S.S.)
Larissa F. Cruz Laboratório de Imunologia Celular Aplicada à Saúde, Fundação Oswaldo Cruz, FIOCRUZ-Rondônia, Porto Velho 76812-245, RO, Brazil; (S.N.S.); (A.S.P.); (M.V.P.); (M.D.S.S.); (J.A.L.); (C.N.B.); (C.P.S.); (H.M.S.); (D.G.C.); (A.V.E.U.); (J.G.S.M.); (L.F.C.); (S.S.S.)
Sulamita S. Setubal Laboratório de Imunologia Celular Aplicada à Saúde, Fundação Oswaldo Cruz, FIOCRUZ-Rondônia, Porto Velho 76812-245, RO, Brazil; (S.N.S.); (A.S.P.); (M.V.P.); (M.D.S.S.); (J.A.L.); (C.N.B.); (C.P.S.); (H.M.S.); (D.G.C.); (A.V.E.U.); (J.G.S.M.); (L.F.C.); (S.S.S.)
Andreimar M. Soares Laboratory of Biotechnology of Proteins and Bioactive Compounds Applied to Health (LABIOPROT), National Institute of Science and Technology in Epidemiology of the Occidental Amazonia0 (INCT-EPIAMO), Oswaldo Cruz Foundation, FIOCRUZ Rondônia, Porto Velho 76801-059, RO, Brazil;
Bruna Cavecci-Mendonça Biotechonology Institute (IBTEC), São Paulo State University, Botucatu 01049-010, SP, Brazil; (B.C.-M.); (L.D.S.)
Lucilene D. Santos Biotechonology Institute (IBTEC), São Paulo State University, Botucatu 01049-010, SP, Brazil; (B.C.-M.); (L.D.S.) Graduate Program in Tropical Diseases and Graduate Program in Medical Biotechnology, Botucatu Medical School (FMB), São Paulo State University, Botucatu 18618-687, SP, Brazil
Juliana P. Zuliani Laboratório de Imunologia Celular Aplicada à Saúde, Fundação Oswaldo Cruz, FIOCRUZ-Rondônia, Porto Velho 76812-245, RO, Brazil; (S.N.S.); (A.S.P.); (M.V.P.); (M.D.S.S.); (J.A.L.); (C.N.B.); (C.P.S.); (H.M.S.); (D.G.C.); (A.V.E.U.); (J.G.S.M.); (L.F.C.); (S.S.S.) Departamento de Medicina, Universidade Federal de Rondônia, Porto Velho 76801-059, RO, Brazil

Collapse

Pérez-Hernández T, Hernández JN, Machín C, McNeilly TN, Nisbet AJ, Matthews JB, Burgess STG, González JF. Exploring the transcriptomic changes underlying recombinant vaccine efficacy against Teladorsagia circumcincta in 3-month-old lambs. Vet Parasitol 2023;320:109960. [PMID: 37269732 DOI: 10.1016/j.vetpar.2023.109960] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2023] [Revised: 05/22/2023] [Accepted: 05/24/2023] [Indexed: 06/05/2023]

Zhao F, Zhang C, Li G, Zheng H, Gu L, Zhou H, Xiao Y, Wang Z, Yu J, Hu Y, Zeng F, Wang X, Zhao Q, Hu J, Yue C, Zhou P, Huang N, Hao Y, Wu W, Cui K, Li W, Li J. A role for whey acidic protein four-disulfide-core 12 (WFDC12) in the pathogenesis and development of psoriasis disease. Front Immunol 2022;13:873720. [PMID: 36148224 PMCID: PMC9485559 DOI: 10.3389/fimmu.2022.873720] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2022] [Accepted: 08/08/2022] [Indexed: 11/13/2022] Open

Affiliation(s)

Fulei Zhao State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, China
Chen Zhang State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, China
Guolin Li State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, China
Huaping Zheng State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, China
Linna Gu State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, China
Hong Zhou State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, China
Yuanyuan Xiao Department of Obstetrics and Gynecology, West China Second Hospital of Sichuan University, Chengdu, China Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu, China
Zhen Wang State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, China
Jiadong Yu State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, China
Yawen Hu State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, China
Fanlian Zeng State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, China
Xiaoyan Wang State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, China
Qixiang Zhao State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, China
Jing Hu State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, China
Chengcheng Yue State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, China
Pei Zhou State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, China
Nongyu Huang State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, China
Yan Hao State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, China
Wenling Wu State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, China
Kaijun Cui Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China
Wei Li Department of Dermatology, Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China
Jiong Li State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, China *Correspondence: Jiong Li,

Collapse

Gilson Sena IF, Fernandes LL, Lorandi LL, Santana TV, Cintra L, Lima IF, Iwai LK, Kramer JM, Birbrair A, Heller D. Identification of early biomarkers in saliva in genetically engineered mouse model C(3)1-TAg of breast cancer. Sci Rep 2022;12:11544. [PMID: 35798767 PMCID: PMC9263110 DOI: 10.1038/s41598-022-14514-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2022] [Accepted: 06/08/2022] [Indexed: 11/09/2022] Open

Visscher MO, Carr AN, Narendran V. Epidermal Immunity and Function: Origin in Neonatal Skin. Front Mol Biosci 2022;9:894496. [PMID: 35755808 PMCID: PMC9215705 DOI: 10.3389/fmolb.2022.894496] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2022] [Accepted: 05/05/2022] [Indexed: 11/22/2022] Open

Abstract

The fascinating story of epidermal immunity begins in utero where the epidermal barrier derives from the ectoderm and evolves through carefully orchestrated biological processes, including periderm formation, keratinocyte differentiation, proliferation, cornification, and maturation, to generate a functional epidermis. Vernix caseosa derives from epidermal cells that mix with sebaceous lipids and coat the fetus during late gestation, likely to provide conditions for cornification. At birth, infants dramatically transition from aqueous conditions to a dry gaseous environment. The epidermal barrier begins to change within hours, exhibiting decreased hydration and low stratum corneum (SC) cohesion. The SC varied by gestational age (GA), transformed over the next 2–3 months, and differed considerably versus stable adult skin, as indicated by analysis of specific protein biomarkers. Regardless of gestational age, the increased infant SC proteins at 2–3 months after birth were involved in late differentiation, cornification, and filaggrin processing compared to adult skin. Additionally, the natural moisturizing factor (NMF), the product of filaggrin processing, was higher for infants than adults. This suggests that neonatal skin provides innate immunity and protection from environmental effects and promotes rapid, continued barrier development after birth. Functional genomic analysis showed abundant differences across biological processes for infant skin compared to adult skin. Gene expression for extracellular matrix, development, and fatty acid metabolism was higher for infant skin, while adult skin had increased expression of genes for the maintenance of epidermal homeostasis, antigen processing/presentation of immune function, and others. These findings provide descriptive information about infant epidermal immunity and its ability to support the newborn’s survival and growth, despite an environment laden with microbes, high oxygen tension, and irritants.

Collapse

López-Martínez MJ, Cerón JJ, Ortín-Bustillo A, Escribano D, Kuleš J, Beletić A, Rubić I, González-Sánchez JC, Mrljak V, Martínez-Subiela S, Muñoz-Prieto A. A Proteomic Approach to Elucidate the Changes in Saliva and Serum Proteins of Pigs with Septic and Non-Septic Inflammation. Int J Mol Sci 2022;23:ijms23126738. [PMID: 35743177 PMCID: PMC9223627 DOI: 10.3390/ijms23126738] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2022] [Revised: 06/10/2022] [Accepted: 06/15/2022] [Indexed: 12/29/2022] Open

Abstract

Sepsis is a systemic inflammatory response triggered by an infectious agent and is recognized by the World Health Organization as a global concern, since it is one of the major causes of severe illness in humans and animals. The study of the changes that can occur in saliva and serum in sepsis can contribute to a better understanding of the pathophysiological mechanisms involved in the process and also to discover potential biomarkers that can help in its diagnosis and monitoring. The objective of this study was to characterize the changes that occur in the salivary and serum proteome of pigs with experimentally-induced sepsis. The study included five pigs with sepsis induced by LPS administration and five pigs with non-septic inflammation induced by turpentine for comparative purposes. In saliva, there were eighteen salivary proteins differentially expressed in the sepsis condition and nine in non-septic inflammation. Among these, significant increments in aldolase A and serpin B12 only occurred in the sepsis model. Changes in aldolase A were validated in a larger population of pigs with sepsis due to Streptococcus suis infection. In serum, there were 30 proteins differentially expressed in sepsis group and 26 proteins in the non-septic group, and most of the proteins that changed in both groups were related to non-specific inflammation. In the saliva of the septic animals there were some specific pathways activated, such as the organonitrogen compound metabolic process and lipid transport, whereas, in the serum, one of the main activated pathways was the regulation of protein secretion. Overall, saliva and serum showed different proteome variations in response to septic inflammation and could provide complementary information about the pathophysiological mechanisms occurring in this condition. Additionally, salivary aldolase A could be a potential biomarker of sepsis in pigs that should be confirmed in a larger population.

Collapse

Affiliation(s)

María José López-Martínez Interdisciplinary Laboratory of Clinical Analysis of the University of Murcia (Interlab-UMU), Department of Animal Medicine and Surgery, Veterinary School, Regional Campus of International Excellence Mare Nostrum, University of Murcia, Espinardo, 30100 Murcia, Spain; (M.J.L.-M.); (A.O.-B.); (D.E.); (I.R.); (S.M.-S.)
José Joaquín Cerón Interdisciplinary Laboratory of Clinical Analysis of the University of Murcia (Interlab-UMU), Department of Animal Medicine and Surgery, Veterinary School, Regional Campus of International Excellence Mare Nostrum, University of Murcia, Espinardo, 30100 Murcia, Spain; (M.J.L.-M.); (A.O.-B.); (D.E.); (I.R.); (S.M.-S.) Correspondence: (J.J.C.); (A.M.-P.)
Alba Ortín-Bustillo Interdisciplinary Laboratory of Clinical Analysis of the University of Murcia (Interlab-UMU), Department of Animal Medicine and Surgery, Veterinary School, Regional Campus of International Excellence Mare Nostrum, University of Murcia, Espinardo, 30100 Murcia, Spain; (M.J.L.-M.); (A.O.-B.); (D.E.); (I.R.); (S.M.-S.)
Damián Escribano Interdisciplinary Laboratory of Clinical Analysis of the University of Murcia (Interlab-UMU), Department of Animal Medicine and Surgery, Veterinary School, Regional Campus of International Excellence Mare Nostrum, University of Murcia, Espinardo, 30100 Murcia, Spain; (M.J.L.-M.); (A.O.-B.); (D.E.); (I.R.); (S.M.-S.)
Josipa Kuleš Clinic for Internal Diseases, Faculty of Veterinary Medicine, University of Zagreb, Heinzelova 55, 10000 Zagreb, Croatia; (J.K.); (A.B.); (V.M.)
Anđelo Beletić Clinic for Internal Diseases, Faculty of Veterinary Medicine, University of Zagreb, Heinzelova 55, 10000 Zagreb, Croatia; (J.K.); (A.B.); (V.M.)
Ivana Rubić Interdisciplinary Laboratory of Clinical Analysis of the University of Murcia (Interlab-UMU), Department of Animal Medicine and Surgery, Veterinary School, Regional Campus of International Excellence Mare Nostrum, University of Murcia, Espinardo, 30100 Murcia, Spain; (M.J.L.-M.); (A.O.-B.); (D.E.); (I.R.); (S.M.-S.)
Juan Carlos González-Sánchez BioQuant, Faculty of Biosciences, Heidelberg University, Im Neuenheimer Feld 267, 69117 Heidelberg, Germany;
Vladimir Mrljak Clinic for Internal Diseases, Faculty of Veterinary Medicine, University of Zagreb, Heinzelova 55, 10000 Zagreb, Croatia; (J.K.); (A.B.); (V.M.)
Silvia Martínez-Subiela Interdisciplinary Laboratory of Clinical Analysis of the University of Murcia (Interlab-UMU), Department of Animal Medicine and Surgery, Veterinary School, Regional Campus of International Excellence Mare Nostrum, University of Murcia, Espinardo, 30100 Murcia, Spain; (M.J.L.-M.); (A.O.-B.); (D.E.); (I.R.); (S.M.-S.)
Alberto Muñoz-Prieto Interdisciplinary Laboratory of Clinical Analysis of the University of Murcia (Interlab-UMU), Department of Animal Medicine and Surgery, Veterinary School, Regional Campus of International Excellence Mare Nostrum, University of Murcia, Espinardo, 30100 Murcia, Spain; (M.J.L.-M.); (A.O.-B.); (D.E.); (I.R.); (S.M.-S.) Clinic for Internal Diseases, Faculty of Veterinary Medicine, University of Zagreb, Heinzelova 55, 10000 Zagreb, Croatia; (J.K.); (A.B.); (V.M.) Correspondence: (J.J.C.); (A.M.-P.)

Collapse

Sun L, Li J, Li X, Yang X, Zhang S, Wang X, Wang N, Xu K, Jiang X, Zhang Y. A Combined RNA Signature Predicts Recurrence Risk of Stage I-IIIA Lung Squamous Cell Carcinoma. Front Genet 2021;12:676464. [PMID: 34194476 PMCID: PMC8236863 DOI: 10.3389/fgene.2021.676464] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2021] [Accepted: 05/20/2021] [Indexed: 12/25/2022] Open

Abstract

Objective

Recurrence remains the main cause of the poor prognosis in stage I-IIIA lung squamous cell carcinoma (LUSC) after surgical resection. In the present study, we aimed to identify the long non-coding RNAs (lncRNAs), microRNAs (miRNAs), and messenger RNAs (mRNAs) related to the recurrence of stage I-IIIA LUSC. Moreover, we constructed a risk assessment model to predict the recurrence of LUSC patients.

Methods

RNA sequencing data (including miRNAs, lncRNAs, and mRNAs) and relevant clinical information were obtained from The Cancer Genome Atlas (TCGA) database. The differentially expressed lncRNAs, miRNAs, and mRNAs were identified using the “DESeq2” package of the R language. Univariate Cox proportional hazards regression analysis and Kaplan-Meier curve were used to identify recurrence-related genes. Stepwise multivariate Cox regression analysis was carried out to establish a risk model for predicting recurrence in the training cohort. Moreover, Kaplan-Meier curves and receiver operating characteristic (ROC) curves were adopted to examine the predictive performance of the signature in the training cohort, validation cohort, and entire cohort.

Results

Based on the TCGA database, we analyzed the differentially expressed genes (DEGs) among 27 patients with recurrent stage I-IIIA LUSC and 134 patients with non-recurrent stage I-IIIA LUSC, and identified 431 lncRNAs, 36 miRNAs, and 746 mRNAs with different expression levels. Out of these DEGs, the optimal combination of DEGs was finally determined, and a nine-joint RNA molecular signature was constructed for clinical prediction of recurrence, including LINC02683, AC244517.5, LINC02418, LINC01322, AC011468.3, hsa-mir-6825, AC020637.1, AC027117.2, and SERPINB12. The ROC curve proved that the model had good predictive performance in predicting recurrence. The area under the curve (AUC) of the prognostic model for recurrence-free survival (RFS) was 0.989 at 3 years and 0.958 at 5 years (in the training set). The combined RNA signature also revealed good predictive performance in predicting the recurrence in the validation cohort and entire cohort.

Conclusions

In the present study, we constructed a nine-joint RNA molecular signature for recurrence prediction of stage I-IIIA LUSC. Collectively, our findings provided new and valuable clinical evidence for predicting the recurrence and targeted treatment of stage I-IIIA LUSC.

Collapse

Zhang L, Wang H, Li N, Hu P, Zhu Z, Wang W, Song Y, Wen Z, Yu X, Zhang S. Label-Free Mass Spectrometry-Based Plasma Proteomics Identified LY6D, DSC3, CDSN, SERPINB12, and SLURP1 as Novel Protein Biomarkers For Pulmonary Tuberculosis. CURR PROTEOMICS 2021. [DOI: 10.2174/1570164617666191210105122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]

Abstract Aim: We aimed to identify new plasma biomarkers for the diagnosis of Pulmonary Tuberculosis (PTB). Background: Tuberculosis is an ancient infectious disease that remains one of the major global health problems. Until now, effective, convenient, and affordable methods for diagnosis of PTB were still lacking. Objective: This study focused on constructing a label-free LC-MS/MS-based comparative proteomics between six tuberculosis patients and six healthy controls to identify Differentially Expressed Proteins (DEPs) in plasma. Methods: To reduce the influences of high-abundant proteins, albumin and globulin were removed from plasma samples using affinity gels. Then DEPs from the plasma samples were identified using a label-free Quadrupole-Orbitrap LC-MS/MS system. The results were analyzed by the protein database search algorithm SEQUEST-HT to identify mass spectra to peptides. The predictive abilities of combinations of host markers were investigated by General Discriminant Analysis (GDA), with Leave-One-Out Cross- Validation (LOOCV). Results: A total of 572 proteins were identified and 549 proteins were quantified. The threshold for DEPs was set as adjusted p-value < 0.05 and fold change ≥1.5 or ≤0.6667, 32 DEPs were found. ClusterVis, TBtools, and STRING were used to find new potential biomarkers of PTB. Six proteins, LY6D, DSC3, CDSN, FABP5, SERPINB12, and SLURP1, which performed well in the LOOCV method validation, were termed as potential biomarkers. The percentage of cross-validated grouped cases correctly classified and original grouped cases correctly classified is greater than or equal to 91.7%. Conclusion: We successfully identified five candidate biomarkers for immunodiagnosis of PTB in plasma, LY6D, DSC3, CDSN, SERPINB12, and SLURP1. Our work supported this group of proteins as potential biomarkers for PTB, and be worthy of further validation. Collapse

Palma C, La Rocca C, Gigantino V, Aquino G, Piccaro G, Di Silvestre D, Brambilla F, Rossi R, Bonacina F, Lepore MT, Audano M, Mitro N, Botti G, Bruzzaniti S, Fusco C, Procaccini C, De Rosa V, Galgani M, Alviggi C, Puca A, Grassi F, Rezzonico-Jost T, Norata GD, Mauri P, Netea MG, de Candia P, Matarese G. Caloric Restriction Promotes Immunometabolic Reprogramming Leading to Protection from Tuberculosis. Cell Metab 2021;33:300-318.e12. [PMID: 33421383 DOI: 10.1016/j.cmet.2020.12.016] [Citation(s) in RCA: 31] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/01/2019] [Revised: 11/13/2020] [Accepted: 12/16/2020] [Indexed: 12/17/2022]

Affiliation(s)

Carla Palma Dipartimento Malattie Infettive, Istituto Superiore di Sanità, 00161 Roma, Italy.
Claudia La Rocca Istituto per l'Endocrinologia e l'Oncologia Sperimentale, Consiglio Nazionale delle Ricerche (IEOS-CNR), 80131 Napoli, Italy
Vincenzo Gigantino Pathology Unit, Istituto Nazionale Tumori, Fondazione G. Pascale, IRCCS, 80131 Naples, Italy
Gabriella Aquino Pathology Unit, Istituto Nazionale Tumori, Fondazione G. Pascale, IRCCS, 80131 Naples, Italy
Giovanni Piccaro Dipartimento Malattie Infettive, Istituto Superiore di Sanità, 00161 Roma, Italy
Dario Di Silvestre Proteomics and Metabolomics Unit, Institute for Biomedical Technologies, Consiglio Nazionale delle Ricerche (ITB-CNR), 20090 Segrate, Milano, Italy
Francesca Brambilla Proteomics and Metabolomics Unit, Institute for Biomedical Technologies, Consiglio Nazionale delle Ricerche (ITB-CNR), 20090 Segrate, Milano, Italy
Rossana Rossi Proteomics and Metabolomics Unit, Institute for Biomedical Technologies, Consiglio Nazionale delle Ricerche (ITB-CNR), 20090 Segrate, Milano, Italy
Fabrizia Bonacina Department of Excellence in Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, 20133 Milano, Italy
Maria Teresa Lepore Istituto per l'Endocrinologia e l'Oncologia Sperimentale, Consiglio Nazionale delle Ricerche (IEOS-CNR), 80131 Napoli, Italy
Matteo Audano Department of Excellence in Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, 20133 Milano, Italy
Nico Mitro Department of Excellence in Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, 20133 Milano, Italy
Gerardo Botti Scientific Directorate, Istituto Nazionale Tumori, Fondazione G. Pascale, IRCCS, 80131 Naples, Italy
Sara Bruzzaniti Istituto per l'Endocrinologia e l'Oncologia Sperimentale, Consiglio Nazionale delle Ricerche (IEOS-CNR), 80131 Napoli, Italy; Dipartimento di Biologia, Università degli Studi di Napoli "Federico II", 80126 Napoli, Italy
Clorinda Fusco Treg Cell Lab, Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli "Federico II", 80131 Napoli, Italy
Claudio Procaccini Istituto per l'Endocrinologia e l'Oncologia Sperimentale, Consiglio Nazionale delle Ricerche (IEOS-CNR), 80131 Napoli, Italy; Unità di Neuroimmunologia, IRCCS-Fondazione Santa Lucia, 00143 Roma, Italy
Veronica De Rosa Istituto per l'Endocrinologia e l'Oncologia Sperimentale, Consiglio Nazionale delle Ricerche (IEOS-CNR), 80131 Napoli, Italy; Unità di Neuroimmunologia, IRCCS-Fondazione Santa Lucia, 00143 Roma, Italy
Mario Galgani Istituto per l'Endocrinologia e l'Oncologia Sperimentale, Consiglio Nazionale delle Ricerche (IEOS-CNR), 80131 Napoli, Italy; Treg Cell Lab, Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli "Federico II", 80131 Napoli, Italy
Carlo Alviggi Istituto per l'Endocrinologia e l'Oncologia Sperimentale, Consiglio Nazionale delle Ricerche (IEOS-CNR), 80131 Napoli, Italy; Department of Neuroscience, Reproductive Science, and Odontostomatology, University of Naples, Federico II, Naples, Italy
Annibale Puca Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, 84081 Baronissi-Salerno, Italy; IRCCS MultiMedica, 20138 Milano, Italy
Fabio Grassi Institute for Research in Biomedicine, Faculty of Biomedical Sciences, Università della Svizzera Italiana, 6500 Bellinzona, Switzerland
Tanja Rezzonico-Jost Institute for Research in Biomedicine, Faculty of Biomedical Sciences, Università della Svizzera Italiana, 6500 Bellinzona, Switzerland
Giuseppe Danilo Norata Department of Excellence in Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, 20133 Milano, Italy; Center for the Study of Atherosclerosis, Società Italiana Studio Aterosclerosi, Bassini Hospital, 20092 Cinisello Balsamo, Milano, Italy
Pierluigi Mauri Proteomics and Metabolomics Unit, Institute for Biomedical Technologies, Consiglio Nazionale delle Ricerche (ITB-CNR), 20090 Segrate, Milano, Italy; Istituto di Scienze della Vita, Scuola Superiore Sant'Anna, 56127 Pisa, Italy
Mihai G Netea Radboud Center for Infectious Diseases and Department of Internal Medicine, Radboud University Medical Center, PO Box 9101, 6500 HB Nijmegen, the Netherlands; Department for Genomics & Immunoregulation, Life and Medical Sciences Institute (LIMES), University of Bonn, 53115 Bonn, Germany
Paola de Candia IRCCS MultiMedica, 20138 Milano, Italy
Giuseppe Matarese Istituto per l'Endocrinologia e l'Oncologia Sperimentale, Consiglio Nazionale delle Ricerche (IEOS-CNR), 80131 Napoli, Italy; Treg Cell Lab, Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli "Federico II", 80131 Napoli, Italy.

Collapse

Goleva E, Calatroni A, LeBeau P, Berdyshev E, Taylor P, Kreimer S, Cole RN, Leung DYM. Skin tape proteomics identifies pathways associated with transepidermal water loss and allergen polysensitization in atopic dermatitis. J Allergy Clin Immunol 2020;146:1367-1378. [PMID: 32360271 DOI: 10.1016/j.jaci.2020.04.022] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2019] [Revised: 04/02/2020] [Accepted: 04/10/2020] [Indexed: 01/16/2023]

Liu M, Zhang J, Wang Y, Xin C, Ma J, Xu S, Wang X, Gao J, Zhang X, Yang S. Non‑invasive proteome‑wide quantification of skin barrier‑related proteins using label‑free LC‑MS/MS analysis. Mol Med Rep 2020;21:2227-2235. [PMID: 32186761 PMCID: PMC7115193 DOI: 10.3892/mmr.2020.11020] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2019] [Accepted: 02/06/2020] [Indexed: 12/11/2022] Open

Oliva S, Laudadio I, Fulci V, Rossetti D, Isoldi S, Stronati L, Carissimi C. SERPINB12 as a possible marker of steroid dependency in children with eosinophilic esophagitis: A pilot study. Dig Liver Dis 2020;52:158-163. [PMID: 31653522 DOI: 10.1016/j.dld.2019.08.018] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/10/2019] [Revised: 06/22/2019] [Accepted: 08/15/2019] [Indexed: 12/11/2022]

Transcriptome Sequencing to Detect the Potential Role of Long Noncoding RNAs in Salt-Sensitive Hypertensive Rats. BIOMED RESEARCH INTERNATIONAL 2019;2019:2816959. [PMID: 31886193 PMCID: PMC6925802 DOI: 10.1155/2019/2816959] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/12/2019] [Accepted: 11/18/2019] [Indexed: 01/11/2023]

Salinas-Torres VM, Salinas-Torres RA, Cerda-Flores RM, Gallardo-Blanco HL, Martínez-de-Villarreal LE. A clinical-pathogenetic approach on associated anomalies and chromosomal defects supports novel candidate critical regions and genes for gastroschisis. Pediatr Surg Int 2018;34:931-943. [PMID: 30094464 DOI: 10.1007/s00383-018-4331-4] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 08/02/2018] [Indexed: 11/30/2022]

Abstract

BACKGROUND

Gastroschisis has been assumed to have a low rate of syndromic and primary malformations. We aimed to systematically review and explore the frequency and type of malformations/chromosomal syndromes and to identify significant biological/genetic roles in gastroschisis.

METHODS

Population-based, gastroschisis-associated anomalies/chromosomal defects published 1950-2018 (PubMed/MEDLINE) were independently searched by two reviewers. Associated anomalies/chromosomal defects and selected clinical characteristics were subdivided and pooled by race, system/region, isolated, and associated cases (descriptive analysis and chi-square test were performed). Critical regions/genes from representative chromosomal syndromes including an enrichment analysis using Gene Ontology Consortium/Panther Classification System databases were explored. Fisher's exact test with False Discovery Rate multiple test correction was performed.

RESULTS

Sixty-eight articles and 18525 cases as a base were identified (prevalence of 17.9 and 3% for associated anomalies/chromosomal defects, respectively). There were 3596 associated anomalies, prevailing those cardiovascular (23.3%) and digestive (20.3%). Co-occurring anomalies were associated with male, female, American Indian, Caucasian, prenatally diagnosed, chromosomal defects, and mortality (P < 0.00001). Gene clusters on 21q22.11 and 21q22.3 (KRTAP), 18q21.33 (SERPINB), 18q22.1 (CDH7, CDH19), 13q12.3 (FLT1), 13q22.1 (KLF5), 13q22.3 (EDNRB), and 13q34 (COL4A1, COL4A2, F7, F10) were significantly related to biological processes: blood pressure regulation and/or vessel integrity, angiogenesis, coagulation, cell-cell and/or cell-matrix adhesion, dermis integrity, and wound healing (P < 0.05).

CONCLUSIONS

Our findings suggest that gastroschisis may result from the interaction of several chromosomal regions in an additive manner as a pool of candidate genes were identified from critical regions supporting a role for vascular disruption, thrombosis, and mesodermal deficiency in the pathogenesis of gastroschisis.

Collapse

Effects of miR-338 on morphine tolerance by targeting CXCR4 in a rat model of bone cancer pain. Biosci Rep 2017;37:BSR20160517. [PMID: 28108674 PMCID: PMC5350600 DOI: 10.1042/bsr20160517] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2016] [Revised: 01/16/2017] [Accepted: 01/20/2017] [Indexed: 01/19/2023] Open

Niehaus JZ, Miedel MT, Good M, Wyatt AN, Pak SC, Silverman GA, Luke CJ. SERPINB12 Is a Slow-Binding Inhibitor of Granzyme A and Hepsin. Biochemistry 2015;54:6756-9. [PMID: 26497600 DOI: 10.1021/acs.biochem.5b01042] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]